Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of apatinib + etoposide in heavily pretreated recurrent epithelial ovarian cancer
ChiCTR1800015637Phase 2Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Nov 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and etoposide in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Hunan Cancer Hospital. Primary endpoint: Overall response rate. Planned start Nov 2017; status: not yet recruiting.
02
Drugs
Rivoceranibetoposide
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR1800015637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015637.